FINNENCE ▪ THE WIRE FILE
THE WIRE · № 84036
Company▲ Bullish
Phase 3 results posted: A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin — Eli Lilly and Company
KINDCompany
DIRECTION▲ Bullish
SOURCES1
ENTITIES2
STORY SIZESTANDALONE
FIRST SEEN
LAST UPDATE
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
Orforglipron Phase 3 results versus dapagliflozin support Lilly's oral diabetes and obesity pipeline.
Oral incretin data strengthens Lilly's metabolic franchise
CATALYST TO WATCH
Regulatory submission and approval timing
MAIN RISK
Comparator trial may not show clear benefit
FULL DISPATCH
Sponsor: Eli Lilly and Company; Status: Completed; Conditions: Type 2 Diabetes; Interventions: Orforglipron, Dapagliflozin; Enrollment: 962 (actual); First posted: 2024-01-05; Results posted: 2026-10-16; NCT: NCT06192108
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
SUBJECTEli Lilly · LLY
AFFECTEDHealthcare
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→CORRELATIONshares LLY, Healthcare
Phase 3 results posted: A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis — Eli Lilly and Company2026-10-16 12:00 UTC
Phase 3 results posted: A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis — Eli Lilly and Company2026-10-16 12:00 UTC
→CORRELATIONshares Healthcare
Scinai Immunotherapeutics Announces Closing of $4.0 Million Financing Through a Private Placement and Warrant Inducement2026-10-16 12:00 UTC
Scinai Immunotherapeutics Announces Closing of $4.0 Million Financing Through a Private Placement and Warrant Inducement2026-10-16 12:00 UTC
→CORRELATIONshares Healthcare
Withings BodyScan 2 Named One of TIME's Best Inventions of 20262026-10-16 12:00 UTC
Withings BodyScan 2 Named One of TIME's Best Inventions of 20262026-10-16 12:00 UTC
→CORRELATIONshares Healthcare
Curis, Inc. Announces Pricing of $8.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules with Existing Healthcare Focused Institutional Investors2026-10-16 12:00 UTC
Curis, Inc. Announces Pricing of $8.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules with Existing Healthcare Focused Institutional Investors2026-10-16 12:00 UTC
→CORRELATIONshares Healthcare
Centene Corporation Demonstrates Commitment to CHOICE Arrangements through Benefit Programs in Indiana, Ohio and Oklahoma2026-10-16 12:00 UTC
Centene Corporation Demonstrates Commitment to CHOICE Arrangements through Benefit Programs in Indiana, Ohio and Oklahoma2026-10-16 12:00 UTC
→CORRELATIONshares Healthcare
Nabsys Launches RepX™ for Repeat Expansion Analysis Ahead of ASHG 20262026-10-16 12:00 UTC
Nabsys Launches RepX™ for Repeat Expansion Analysis Ahead of ASHG 20262026-10-16 12:00 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.